Short Interest in AlloVir, Inc. (NASDAQ:ALVR) Drops By 12.0%

AlloVir, Inc. (NASDAQ:ALVR) was the target of a significant decrease in short interest in December. As of December 15th, there was short interest totalling 1,690,000 shares, a decrease of 12.0% from the November 30th total of 1,920,000 shares. Based on an average daily volume of 354,200 shares, the days-to-cover ratio is presently 4.8 days.

AlloVir Price Performance

AlloVir stock traded down $0.01 during trading hours on Monday, hitting $0.45. The company had a trading volume of 127,658 shares, compared to its average volume of 587,370. AlloVir has a fifty-two week low of $0.40 and a fifty-two week high of $1.05. The firm’s fifty day moving average is $0.62 and its 200-day moving average is $0.71. The firm has a market capitalization of $51.91 million, a P/E ratio of -0.51 and a beta of 0.59.

AlloVir (NASDAQ:ALVR) last released its earnings results on Tuesday, November 12th. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.10.

Hedge Funds Weigh In On AlloVir

A hedge fund recently bought a new stake in AlloVir stock. Point72 Asia Singapore Pte. Ltd. acquired a new stake in AlloVir, Inc. (NASDAQ:ALVR) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor acquired 76,278 shares of the company’s stock, valued at approximately $55,000. Point72 Asia Singapore Pte. Ltd. owned 0.07% of AlloVir at the end of the most recent quarter. 66.05% of the stock is currently owned by institutional investors and hedge funds.

AlloVir Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.